John Claude
John Claude Cadotte, Jr., Waterboro, ME US
Patent application number | Description | Published |
---|---|---|
20150084217 | MICRO-FEATURE METHODS FOR OVER-MOLDING SUBSTRATE - A method of making a microplate, including: injection molding a resin to form a substrate ( | 03-26-2015 |
20150085365 | LOW BIREFRINGENT SENSOR SUBSTRATE AND METHODS THEREOF - A resonant waveguide article, including: a polymeric substrate having at least one integral grating region, wherein the article has a low birefringence property of for example, from about 5 to 270 nm/cm, as defined herein. Also disclosed is a microplate including the resonant waveguide article, and an integral well plate bonded to the sensor article, as defined herein. Also disclosed are methods of making a sensor article, and a method of making and using the microplate including the sensor article, as defined herein. | 03-26-2015 |
John Claude Elfar, Rochester, NY US
Patent application number | Description | Published |
---|---|---|
20150031991 | Depth Advancement Marker Needle For Image Guided Procedures - Many image guided needle procedures use ultrasound, computed tomography (CT) magnetic resonance imaging (MRI) or other imaging systems. In such procedures, there is currently a preference for long axis injections and related procedures where the long axis of the needle is parallel to the plane of the two dimensional images created by the imaging system. This is due to the fact that long axis imaging of a needle provides good visual indication of depth of penetration of the needle, whereas short axis imaging shows only a dot or small circle, which is the cross section of the needle and provides no depth of penetration information. Many procedures, however, benefit from, or require the use of, short axis imaging. | 01-29-2015 |
John Claude Savoir, Coyocan MX
Patent application number | Description | Published |
---|---|---|
20090081303 | PHARMACEUTICAL FORMULATION FOR CONTRACEPTION AND HORMONE-REPLACEMENT THERAPY - The present invention provides slow release estradiol-progesterone formulations that can be used in either contraception or hormone replacement therapies. The formulations comprise shaped particles of estradiol that is in a hemicrystalline form that exhibits especially low dissolution rates. The shaped particles comprise estradiol compounded in a 1:1 molar ratio with cholesterol, and are administered in combination with progesterone. The slow release formulations of the present invention afford the dual advantages of a low dose estradiol formulation with a low frequency administration regimen. The formulations can be parenterally administered once a month or less often. | 03-26-2009 |
John Claude Savoir Vilboeuf, Mexico City MX
Patent application number | Description | Published |
---|---|---|
20110033536 | 24-HOUR SUSTAINED-RELEASE METOCLOPRAMIDE - The present invention consists of an extended-release metoclopramide hydrochloride pharmaceutical composition, in 30 mg drug substance 5 tablets, for use in gastrointestinal disorders. The formulation is mainly composed of a hydrophilic polymer, a hydrophobic polymer, a hydrophilic component and metoclopramide hydrochloride. The hydrophilic polymer is swollen by hydration when contacting water, forming a gel coat which controls drug substance release. The water inside the matrix dissolves the drug substance and this is diffused outside through the gel coat. The hydrophobic polymer shows plastic deformation properties under compression, tending to surround the drug substance particles reducing the pore quantity and dimensions in the matrix structure, delaying as a consequence the drug substance release. The hydrophilic component is part of the gel coating structure providing support thereto. Drug substance is the metoclopramide hydrochloride or a pharmaceutically acceptable salt thereof. | 02-10-2011 |
20110104289 | METHOD AND PHARMACEUTICAL COMPOSITION FOR OBTAINING THE PLASMATIC PROGESTERONE LEVELS REQUIRED FOR DIFFERENT THERAPEUTIC INDICATIONS - The invention relates to the development of a method and pharmaceutical compositions for obtaining plasmatic progesterone levels in humans and for maintaining a plasmatic progesterone concentration between 42 and 3.5 ng/mL for eight days as well as maximum plasmatic concentrations (Cmax) between 12 and 42 ng/mL, sufficient for use in different therapeutic options that require said progesterone concentrations. | 05-05-2011 |
20110207823 | 12-HOUR SUSTAINED-RELEASE METOCLOPRAMIDE - The present invention consists of an extended-release metoclopramide hydrochloride pharmaceutical composition, in 15 mg drug substance tablets, for use in gastrointestinal disorders. The formulation is mainly composed of a hydrophilic polymer, a hydrophobic polymer, a hydrophilic component and metoclopramide hydrochloride. The hydrophilic polymer is swollen by hydration when contacting water, forming a gel coat which controls drug substance release. The water inside the matrix dissolves the drug substance and this is diffused outside through the gel coat. The hydrophobic polymer shows plastic deformation properties under compression, tending to surround the drug substance particles reducing the pore quantity and dimensions in the matrix structure, delaying as a consequence the drug substance release. The hydrophilic component is part of the gel coating structure providing support thereto. Drug substance is the metoclopramide hydrochloride or a pharmaceutically acceptable salt thereof. | 08-25-2011 |
John Claude Savoir Vilboeuf, Mexico D.f. MX
Patent application number | Description | Published |
---|---|---|
20130344145 | ORALLY ADMINISTERED PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME, COMPRISING AN INTESTINAL MOTILITY MODIFIER, AN AGENT THAT PREVENTS GAS RETENTION, AND DIGESTIVE ENZYMES, AND PREPARATION METHOD THEREOF - A pharmaceutical composition or formulation adapted for oral administration in tablet, coated tablet, capsule or reconstitutable powder form for the prevention or treatment of intestinal disorders such irritable bowel syndrome, also known as irritable colon syndrome, based on an intestinal motility modifier, an agent that prevents gas retention, of digestive enzymes, a binding agent, a diluting agent, an absorbent agent, a lubricant, aglidant, and an disintegrating agent or suspending agent, effective in the normalization of intestinal disorders, to achieve an analgesic activity, to achieve an anti-spasmic activity and to reduce the symptoms associated with intestinal gas such as distention, abdominal pain and flatulence. | 12-26-2013 |